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Abstract: A novel series of {4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-
1-yl}alkylphosphonates and {4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-
triazol-1-yl}alkylphosphonates as acyclic analogues of guanosine were synthesized and 
assessed for antiviral activity against a broad range of DNA and RNA viruses and for their 
cytostatic activity toward three cancerous cell lines (HeLa, L1210 and CEM). They were devoid 
of antiviral activity; however, several phosphonates were found slightly cytostatic against 
HeLa cells at an IC50 in the 80–210 µM range. Compounds (1R,2S)-17k and (1S,2S)-17k 
showed the highest inhibitory effects (IC50 = 15–30 µM) against the proliferation of murine 
leukemia (L1210) and human T-lymphocyte (CEM) cell lines. 
Keywords: azidophosphonates; acyclonucleotides; 1,2,3-triazoles; cycloaddition; antiviral; 
cytostatic 
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1. Introduction 
An effective treatment for viral infections is one of the most difficult goals of contemporary medicine. 
The discovery of acyclic nucleosides/nucleotides, which act as antimetabolites, had a significant impact 
on the progress in the therapy of viral infections [1,2]. Among them, adefovir is active against DNA 
viruses and retroviruses [3–5], whereas tenofovir exhibits high potency and selectivity against HIV-1 
and HIV-2 viruses and hepatitis B virus [6,7]. Ganciclovir [8–10] and its prodrug with improved oral 
bioavailability, valganciclovir [11,12], are used for the treatment of cytomegalovirus infections. 
Cidofovir [5,13,14] shows activity against herpes viruses, including cytomegalovirus, as well as adeno- 
and pox-viruses. The specificity of the antiviral activity of the compounds already known strongly depends 
on the structural features of the aliphatic chain installed as a sugar ring replacer, whereas a choice of 
nucleobases is mostly limited to adenine, guanine and 2,6-diaminopurine. Various guanine-containing 
analogues of nucleosides have been reported as potent antiviral agents (Figure 1) [15–30]. Moreover, 
acyclic analogues of nucleotides having guanine and hypoxanthine as a nucleobase with antimalarial 
activity have also been reported [26,31]. Phosphorylation of nucleosides and their structural analogues 
is inefficient, and at the same time, it appears to be one of the most important steps with implications on 
their activity, since the first step of phosphorylation is carried out by viral kinases. Therefore, several 
nucleotide analogues have been designed by incorporation of a phosphonate residue ((RO)2P(O)–CH2–) 
instead of a phosphate group ((RO)2P(O)–O–C(5′)) to avoid the first phosphorylation step and to ensure 
the stability of phosphonates to enzymatic hydrolysis [32–35]. 
 
Figure 1. Known biologically-active acyclic analogues of guanosine. 
In recent years, analogues of nucleotides containing various modifications of an acyclic fragment 
have been widely studied. Among them, extended linkers, including a 1,2,3-triazole moiety, were 
synthesized [36–40], and several compounds with promising anticancer (1–3) [38] and antiviral  
(3–8) [37–39] properties were found. Although various canonical nucleobases and their mimetics were 
applied, only a few acyclic guanosine, as well as 2-amino-6-chloropurine analogues containing the 
1,2,3-triazole linker (9–13) have been obtained so far (Figure 2) [36,40‒43]; however, among them, only 
Compound 13 was tested and revealed inhibitory activity against thymidine phosphorylase [40]. 
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Figure 2. Examples of acyclic nucleotide analogues containing the 1,2,3-triazole linker. 
As a continuation of our ongoing project directed towards biologically-active acyclic analogues  
of nucleotides with the 1,2,3-triazole linker, a new series of analogues 16 and 17 containing 2-amino-
6-chloropurine and guanine as nucleobases has been designed to study their antiviral and cytostatic 
properties. To install a guanine moiety at C4 in the 1,2,3-triazole ring, two strategies were used. The 
dipolar cycloaddition of the respective azidoalkylphosphonates 14 to propargylated guanines should 
directly lead to Compound 15 or 16 [41–43], whereas application of 2-amino-6-chloro-9-propargylpurine 
as dipolarophile in the reaction with azides 14 should produce Compound 17 to be subsequently 
transformed into 16 [40,44–47] (Scheme 1). 
 
Scheme 1. Retrosynthesis of acyclic phosphonate guanosine analogues. 
Generally, in order to secure sufficient bioavailability of active phosphonate nucleotide analogues, 
they are administered as prodrugs, namely the respective phosphonate esters or amides [33–35,48–53]. 
For this reason, we designed guanosine analogues 16 and 17 as the respective phosphonate esters to 
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ensure sufficient membrane permeability. Moreover, our recent experiences clearly supported the strategy 
to prepare diesters rather than free phosphonic acids, which are completely ionized at physiological 
pH. Indeed, we found several examples of active diesters in the class of 1,2,3-triazole phosphonates, 
whereas the respective free acids appeared inactive [38,39,54]. 
2. Results and Discussion 
2.1. Chemistry 
Propargylated 2-amino-6-chloropurine 19 [29,36,40,45,55], guanine 18a [29,44–47,55] and  
N2-acetylguanine 18b [42,43,56], as well as all azidoalkylphosphonates 14a–k [37,38,57–62] are known 
compounds and were obtained according to the literature procedures. 
Although cycloadditions of propargylated guanines 18a (R = H) and 18b (R = Ac) to various azides 
have previously been mentioned [41–43], in our hands, the reaction of 18a, as well as 18b with the 
azidomethylphosphonate 14a failed because of the low solubility of guanines 18a and 18b (Scheme 2). 
Attempts at running a cycloaddition of the phosphonate 14a with propargylguanine 18a at 110 °C in 
toluene resulted in the recovery of starting materials only. Similarly, when the 3-azidopropylphosphonate 
14c was treated with 18a or 18b at 110 °C in toluene, as well as under microwave (MW) irradiation in 
aqueous ethanol, no traces of cycloadducts were observed. 
 
Scheme 2. Attempts at synthesizing acyclic guanosine analogues from guanines 18a and 
18b. Reaction and conditions: (a) Toluene, reflux, 72 h; (b) CuSO4 × 5H2O, sodium ascorbate, 
EtOH–H2O, 35–40 °C, 3 h, microwave (MW). 
For this reason, we turned to 2-amino-6-chloro-9-propargylpurine 19, which was found to be 
sufficiently soluble in the reaction medium and reacted with the respective ω-azidoalkylphosphonates 
14 to form the intermediate 2-amino-6-chloropurines 17, which were transformed into guanine analogues 
in the last step. Thus, azides 14 were subjected to cycloaddition with Compound 19 in the presence  
of Cu(I) salt under microwave irradiation to give 1,2,3-triazoles 17a–k. Reactions were complete at 
35–40 °C within 15 min (Scheme 3). Subsequently, 17a–k were treated with 75% trifluoroacetic  
acid to provide acyclic guanosine analogues 16a–k in good yields (92%–98%). However, attempts at 
preparing (1R,2S)-16k and (1S,2S)-16k failed, since the treatment of (1R,2S)-17k and (1S,2S)-17k with 
trifluoroacetic acid led to severe decomposition. All final compounds were purified by chromatography, 
 
Molecules 2015, 20 18793 
 
 
and solids were finally recrystallized; their purity was ascertained by NMR spectroscopic methods and 
elemental analysis. 
 
Scheme 3. Synthesis of Compounds 17a‒k and 16a‒j. Reaction and conditions: (a) 2-amino-
6-chloro-9-propargylpurine 19, CuSO4 × 5H2O, sodium ascorbate, EtOH–H2O, 35–40 °C, 
15 min, microwave (MW); (b) 75% TFA, 24 h, r.t. 
2.2. Antiviral Activity and Cytostatic/Cytotoxic Evaluation 
All phosphonates 16a–j and 17a–k were evaluated for their antiviral activities against a wide variety 
of DNA and RNA viruses using the following cell-based assays: (1) human embryonic lung (HEL) cell 
cultures: herpes simplex virus-1 (KOS), herpes simplex virus-2 (G), vaccinia virus, vesicular stomatitis 
virus, herpes simplex virus-1 (TK− KOS ACVr) and adenovirus-2, cytomegalovirus (AD-169 strain and 
Davis strain) and varicella-zoster virus (TK+ VZV stain and TK− VZV stain); (2) HeLa cell cultures: 
vesicular stomatitis virus, Coxsackie virus B4 and respiratory syncytial virus; (3) Vero cell cultures: 
para-influenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus; (4) Crandell-Rees 
feline kidney (CRFK) cell cultures: feline corona virus (FIPV) and feline herpesvirus (FHV); and  
(5) Madin-Darby canine kidney (MDCK) cell cultures: influenza A virus H1N1 subtype, influenza A 
virus H3N2 subtype and influenza B virus. Ganciclovir, cidofovir, acyclovir, brivudine, (S)-9-(2,3-
dihydroxypropyl)adenine ((S)-DHPA), Hippeastrum hybrid agglutinin (HHA), Urtica dioica agglutinin 
(UDA), dextran sulfate (molecular weight 5000, DS-5000), ribavirin, oseltamivir carboxylate, amantadine 
and rimantadine were used as the reference compounds. The antiviral activity was expressed as the EC50: 
the compound concentration required to reduce virus-induced cytopathogenicity by 50%. Unfortunately, 
no inhibitory activity against any virus was detected for the evaluated compounds at 250 µM. 
The cytotoxicity of the tested compounds toward the uninfected host cells was defined as the 
minimum cytotoxic concentration (MCC) that causes a microscopically-detectable alteration of normal 
cell morphology. The 50% cytotoxic concentration (CC50), causing a 50% decrease in cell viability, 
was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) assay system. The cytostatic activity of the tested compounds was 
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defined as the 50% cytostatic inhibitory concentration (IC50), causing a 50% decrease in cell proliferation, 
and was determined against murine leukemia L1210, human T-lymphocyte CEM and human cervix 
carcinoma HeLa cells (Table 1). 
Table 1. Inhibitory effect of the tested compounds against the proliferation of murine 
leukemia (L1210), human T-lymphocyte (CEM) and human cervix carcinoma cells (HeLa). 
Compounds 16a–k and 17a–k
IC50 a (µM) 
L1210 CEM HeLa 
17a 283 ± 17 ≥250 ≥250 
17b ≥250 >250 227 ± 32 
17c 227 ± 32 >250 ≥250 
17d >250 >250 ≥250 
17e >250 >250 >250 
17f >250 >250 >250 
17g >250 >250 >250 
17h >250 ≥250 >250 
17i >250 >250 >250 
17j >250 >250 >250 
(1R,2S)-17k 21 ± 2 26 ± 8 90 ± 33 
(1S,2S)-17k 16 ± 6 30 ± 16 84 ± 12 
16a >250 >250 >250 
16b >250 >250 >250 
16c >250 >250 138 ± 52 
16d >250 >250 148 ± 25 
16e >250 >250 206 ± 49 
16f >250 >250 195 ± 78 
16g >250 >250 185 ± 35 
16h >250 >250 ≥250 
16i >250 >250 210 ± 13 
16j >250 >250 212 ± 54 
5-fluorouracil 0.33 ± 0.17 18 ± 5 0.54 ± 0.12 
a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%. 
None of the tested compounds affected cell morphology of HEL, HeLa, Vero, MDCK and CRFK 
cells at concentrations up to 100 μM. Instead, several compounds appeared slightly cytostatic, selectively 
against HeLa cells at an IC50 in the 80–210 µM range. From the entire library of compounds, only 
(1R,2S)-17k and (1S,2S)-17k appeared to be the most active toward all tested cancerous cell lines, and 
they showed the highest inhibitory effect (IC50 = 16–30 µM) against the proliferation of murine leukemia 
(L1210) and human T-lymphocytes (CEM).  
The significantly higher activity of dibenzyl phosphonates (1R,2S)-17k and (1S,2S)-17k is probably 
due to their better penetration through cell membranes when compared to the other compounds in the 
series 17, as well as 16, which all were tested as diethyl esters. 
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3. Experimental Section 
3.1. General 
1H-NMR were taken in CDCl3 or CD3OD on the following spectrometers: Varian Mercury-300 
(Varian NMR Instrument, Palo Alto, CA, USA) with TMS as an internal standard; chemical shifts δ in 
ppm with respect to TMS; coupling constants J in Hz. 13C-NMR spectra were recorded on Varian 
Mercury-300 (Varian NMR Instrument, Palo Alto, CA, USA) and Bruker Avance III spectrometers 
(Bruker Instruments, Karlsruhe, Germany) at 75.5 and 151 MHz, respectively. 31P-NMR spectra were 
taken in CDCl3 or CD3OD on a Varian Mercury-300 (Varian NMR Instrument, Palo Alto, CA, USA) 
at 121.5 MHz. 
IR spectral data were measured on an Infinity MI-60 FT-IR spectrometer (ATI Instruments North 
America—Mattson, Madison, WI, USA). Melting points were determined on a Boetius apparatus (VEB 
Kombinat NAGEMA, Dresden, DDR—Currently Germany) and are uncorrected. Elemental analyses 
were performed by the Microanalytical Laboratory of this faculty on a Perkin Elmer PE 2400 CHNS 
analyzer (Perkin-Elmer Corp., Norwalk, CT, USA). 
The following adsorbents were used: column chromatography, Merck silica gel 60 (70–230 mesh); 
analytical TLC, Merck TLC plastic sheets silica gel 60 F254. TLC plates were developed in 
chloroform−methanol solvent systems. Visualization of spots was effected with iodine vapors. All 
solvents were purified by methods described in the literature. 
Microwave irradiation experiments were carried out in 50-mL glass vials in a microwave reactor 
Plazmatronika RM 800 (Plazmatronika, Wrocław, Poland). 
3.2. General Procedure for the Synthesis of 17a–k 
To a solution of the respective azidoalkylphosphonate 14 (1.00 mmol) in EtOH (1 mL) and H2O (1 mL), 
CuSO4 × 5H2O (0.05 mmol), sodium ascorbate (0.10 mmol) and 2-amino-6-chloro-9-propargyl-purine 
(1.00 mmol) were added. The suspension was irradiated in the microwave reactor (Plazmatronika RM 
800, 800 W, Plazmatronika, Wrocław, Poland) at 35–40 °C for 15 min. Solvents were removed by 
vacuum evaporation, and the residue was suspended in chloroform (5 mL) and filtered through a layer of 
Celite. The solution was concentrated in vacuo, and the crude product was purified on a silica gel column 
with chloroform–methanol mixtures (50:1, 20:1 or 10:1, v/v) to give the appropriate 1,2,3-triazoles 17. 
Diethyl {4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}methylphosphonate (17a): 
A white solid (after crystallization from ethyl acetate), yield 88%; m.p. = 138–139 °C; IR (KBr):  
ν = 3327, 3211, 2988, 1796, 1613, 1565, 1518, 1468, 1408, 1241 cm−1; 1H-NMR (300 MHz, CDCl3):  
δ = 7.94 (d, J = 0.8 Hz, 1H, HC5′), 7.93 (s, 1H), 5.38 (s, 2H, CH2), 5.31 (s, 2H, NH2), 4.76 (d, J = 13.3 Hz, 
2H, PCH2), 4.15–4.04 (m, 4H, 2 × POCH2CH3), 1.26 (t, J = 6.9 Hz, 3H, POCH2CH3); 1.25 (t, J = 6.9 Hz, 
3H, POCH2CH3); 13C-NMR (75.5 MHz, CDCl3): δ = 159.43, 153.44, 150.97, 142.27, 142.18, 124.63, 
124.52 (d, J = 5.2 Hz, C5′), 63.81 (d, J = 6.6 Hz, POC), 46.08 (d, J = 155.2 Hz, PC), 38.70, 16.46 (d,  
J = 5.5 Hz, POCC), 16.42 (d, J = 5.5 Hz, POCC); 31P-NMR (121.5 MHz, CDCl3): δ = 15.93 ppm. 
Anal. calcd. for C13H18ClN8O3P: C, 38.96; H, 4.53; N, 27.96. Found: C, 38.97; H, 4.33; N, 27.72. 
Molecules 2015, 20 18796 
 
 
Diethyl 2-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}ethylphosphonate (17b): A 
white solid (after crystallization from ethyl acetate), yield 91%; m.p. = 145–146 °C; IR (KBr): ν = 3325, 
3211, 2985, 1796, 1613, 1565, 1518, 1468, 1408, 1223, 1050 cm−1; 1H-NMR (300 MHz, CDCl3): δ = 7.94 
(s, 1H, HC5′), 7.76 (s, 1H), 5.37 (s, 2H, CH2), 5.21 (s, 2H, NH2), 4.62 (dt, J = 13.4 Hz, J = 7.4 Hz, 2H, 
PCH2CH2), 4.10–4.00 (m, 4H, 2 × POCH2CH3), 2.40 (dt, J = 18.3 Hz, J = 7.4 Hz, 2H, PCH2), 1.26 (t, 
J = 7.1 Hz, 6H, POCH2CH3); 13C-NMR (75.5 MHz, CDCl3): δ = 159.36, 153.34, 150.93, 142.19, 142.13, 
141.81, 124.58, 123.73 (d, J = 4.0 Hz, C5′), 62.34 (d, J = 6.6 Hz, POC), 44.74 (PCC), 38.55, 26.99 (d, 
J = 141.4 Hz, PC), 16.44 (d, J = 5.7 Hz, POCC), 16.40 (d, J = 5.7 Hz, POCC); 31P-NMR (121.5 MHz, 
CDCl3): δ = 25.81 ppm. Anal. calcd. for C14H20ClN8O3P: C, 40.54; H, 4.86; N, 27.01. Found: C, 40.63; 
H, 4.60; N, 27.04. 
Diethyl 3-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}propylphosphonate (17c): 
White powder, yield 86%; m.p. = 74–76 °C; IR (KBr): ν = 3390, 3210, 2985, 1797, 1617, 1564, 1468, 
1409, 1215, 1025 cm−1; 1H-NMR (300 MHz, CDCl3): δ = 7.94 (s, 1H, HC5′), 7.72 (s, 1H), 5.37 (s, 2H, 
CH2), 5.28 (s, 2H, NH2), 4.46 (t, J = 6.9 Hz, 2H, PCH2CH2CH2), 4.14–4.02 (m, 4H, 2 × POCH2CH3), 
2.21 (dqu, J = 18.7 Hz, J = 6.9 Hz, 2H, PCH2CH2), 1.69 (dt, J = 18.7 Hz, J = 7.9 Hz, 2H, PCH2), 1.31 
(t, J = 7.2 Hz, 6H, POCH2CH3); 13C-NMR (75.5 MHz, CDCl3): δ = 159.34, 153.42, 151.09, 142.24, 
142.18, 141.93, 124.79, 123.49 (d, J = 3.1 Hz, C5′), 62.07 (d, J = 6.6 Hz, POC), 50.16 (d, J = 14.6 Hz, 
PCCC), 38.69, 23.67 (d, J = 4.6 Hz, PCC), 22.46 (d, J = 142.9 Hz, PC), 16.62 (d, J = 5.7 Hz, POCC), 
16.56 (d, J = 5.7 Hz, POCC); 31P-NMR (121.5 MHz, CDCl3): δ = 30.26 ppm. Anal. calcd. for 
C15H22ClN8O3P: C, 42.01; H, 5.17; N, 26.13. Found: C, 41.92; H, 5.14; N, 25.83. 
Diethyl 4-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}butylphosphonate (17d): 
Colorless oil, yield 93%; IR (film): ν = 3324, 3210, 2983, 1613, 1562, 1467, 1408, 1215, 1025 cm−1; 
1H-NMR (300 MHz, CDCl3): δ = 7.94 (s, 1H, HC5′), 7.65 (s, 1H), 5.37 (s, 2H, CH2), 5.40–5.00 (very 
br s, 2H, NH2), 4.36 (t, J = 6.9 Hz, 2H, PCCCCH2), 4.20–4.00 (m, 4H, 2 × POCH2CH3), 2.02 (qu,  
J = 6.9 Hz, 2H, PCCCH2), 1.80–1.60 (m, 4H, PCCH2 and PCH2), 1.30 (t, J = 7.0 Hz, 6H,  
2 × POCH2CH3); 13C-NMR (151 MHz, CDCl3): δ = 159.47, 153.50, 151.01, 142.26, 141.95, 124.67, 
123.06, 61.69 (d, J = 6.6 Hz, 2 × POC), 49.76, 38.54, 30.43 (d, J = 15.0 Hz, PCCC), 24.66 (d,  
J = 141.9 Hz, PC), 19.48 (d, J = 4.9 Hz, PCC), 16.30 (d, J = 6.0 Hz, POCC); 31P-NMR (121.5 MHz, 
CDCl3): δ = 31.33 ppm. Anal. calcd. for C16H24ClN8O3P: C, 43.40; H, 5.46; N, 25.30. Found: C, 43.21; 
H, 5.40; N, 25.23. 
Diethyl 2-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-hydroxyethylphosphonate 
(17e): White solid (after column chromatography and crystallization from ethyl acetate), yield 81%; 
m.p. = 174–175 °C; IR (KBr): ν = 3433, 3218, 2986, 1618, 1565, 1468, 1409, 1215, 1021 cm−1;  
1H-NMR (300 MHz, CDCl3): δ = 7.86 (s, 1H, HC5′), 7.83 (s, 1H), 5.40 (br t, J = 4.6 Hz, 1H, OH), 5.73 
(s, 2H, NH2), 5.21 (AB, JAB = 15.5 Hz, 1H, HCH), 5.20 (AB, JAB = 15.5 Hz, 1H, HCH), 4.85–4.76 (m, 
1H), 4.51–4.38 (m, 2H), 4.27–4.14 (m, 4H, 2 × POCH2CH3), 1.35 (t, J = 7.0 Hz, 3H, POCH2CH3), 
1.33 (t, J = 7.0 Hz, 3H, POCH2CH3); 13C-NMR (75.5 MHz, CDCl3): δ = 159.50, 153.13, 150.61, 
142.43, 141.49, 125.41, 123.93, 66.75 (d, J = 167.2 Hz, PC), 63.64 (d, J = 7.2 Hz, POC), 63.56 (d,  
J = 7.2 Hz, POC), 52.02 (PCC), 38.56, 16.63 (d, J = 5.7 Hz, 2 × POCC); 31P-NMR (121.5 MHz, 
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CDCl3): δ = 20.67 ppm. Anal. calcd. for C14H20ClN8O4P: C, 39.03; H, 4.68; N, 26.01. Found: C, 39.25; 
H, 4.42; N, 26.05. 
Diethyl 3-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-2-hydroxypropylphosphonate 
(17f): Colorless oil, yield 89%; IR (film): ν = 3346, 3218, 3218, 2985, 1618, 1564, 1468, 1409, 1220, 
1025 cm−1; 1H-NMR (300 MHz, CDCl3): δ = 7.93 (s, 1H, HC5′), 7.87 (s, 1H), 5.30 (s, 4H, CH2 and NH2), 
4.60–4.47 (m, 1H, PCCCHaHb), 4.45–4.30 (m, 1H, PCCCHaHb), 4.20–4.00 (m, 4H, 2 × POCH2CH3), 
2.10–1.70 (m, 4H, OH, PCH2), 1.33 (t, J = 7.1 Hz, 3H, POCH2CH3), 1.31 (t, J = 7.1 Hz, 3H, POCH2CH3); 
13C-NMR (75.5 MHz, CDCl3): δ = 159.44, 153.33, 150.71, 142.46, 141.58, 125.14, 124.27, 65.46 
(PCC), 62.50 (d, J = 6.3 Hz, POC), 62.32 (d, J = 6.6 Hz, POC), 56.21 (d, J = 15.2 Hz, PCCC), 38.65, 31.09 
(d, J = 139.7 Hz, PC), 16.53 (d, J = 6.8 Hz, 2 × POCC); 31P-NMR (121.5 MHz, CDCl3): δ = 28.62 ppm. 
Anal. calcd. for C15H22ClN8O4P: C, 40.50; H, 4.99; N, 25.19. Found: C, 40.55; H, 5.06; N, 25.30. 
Diethyl 3-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-hydroxypropylphosphonate 
(17g): White powder, yield 95%; m.p. = 124–126 °C; IR (KBr): ν = 3405, 3217, 2983, 1618, 1563, 
1468, 1409, 1217, 1022 cm−1; 1H-NMR (300 MHz, CDCl3): δ = 8.01 (s, 1H, HC5′), 7.75 (s, 1H), 5.38 
(s, 2H, CH2), 4.58 (dd, J = 7.5 Hz, J = 5.8 Hz, 2H, PCCCH2), 4.21–4.08 (m, 4H, 2 × POCH2CH3), 3.77 
(ddd, J = 12.4 Hz, J = 6.2 Hz, J = 3.2 Hz, 1H, PCH), 2.44–2.14 (m, 4H, PCCH2 and NH2), 1.32 (t,  
J = 7.1 Hz, 3H, POCH2CH3), 1.29 (t, J = 7.1 Hz, 3H, POCH2CH3); 13C-NMR (151 MHz, CDCl3):  
δ = 160.33, 153.68, 150.22, 142.80, 142.24, 124.02, 123.42, 63.67 (d, J = 168.2 Hz, PC), 63.00 (d,  
J = 7.0 Hz, POC), 62.65 (d, J = 7.0 Hz, POC), 46.30 (d, J = 15.6 Hz, PCCC), 38.05, 31.70 (d, J = 4.0 Hz, 
PCC) 15.40 (d, J = 5.5 Hz, POCC), 15.30 (d, J = 5.5 Hz, POCC); 31P-NMR (121.5 MHz, CDCl3):  
δ = 24.00 ppm. Anal. calcd. for C15H22ClN8O4P: C, 40.50; H, 4.99; N, 25.19. Found: C, 40.54; H, 4.79; 
N, 24.97. 
Diethyl 2-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-ethoxymethylphosphonate 
(17h): Colorless oil, yield 88%; IR (film): ν = 2988, 1798, 1633, 1614, 1470, 1410, 1220, 1025 cm−1; 
1H-NMR (300 MHz, CDCl3): δ = 8.02 (s, 1H, HC5′), 7.96 (s, 1H), 5.37 (s, 2H, CH2), 4.56 (t, J = 4.8 Hz, 
2H, PCH2OCH2CH2), 4.18–4.08 (m, 4H, 2 × POCH2CH3), 3.95 (t, J = 4.8 Hz, 2H, PCOCH2CH2), 3.77 
(d, J = 8.7 Hz, 2H, PCH2O), 2.00 (br s, 2H, NH2), 1.31 (t, J = 7.2 Hz, 6H, 2 × POCH2CH3); 13C-NMR 
(151 MHz, CDCl3): δ = 159.53, 153.55, 151.00, 142.22, 141.87, 124.69, 124.44, 71.10 (d, J = 11.7 Hz, 
PCOC), 65.18 (d, J = 168.2 Hz, PC), 62.61 (d, J = 6.6 Hz, POC), 50.10, 38.58, 16.37 (d, J = 5.5 Hz, 
POCC); 31P-NMR (121.5 MHz, CDCl3): δ = 20.60 ppm. Anal. calcd. for C15H22ClN8O4P: C, 40.50; H, 
4.99; N, 25.19. Found: C, 40.37; H, 4.80; N, 25.10. 
Diethyl 2-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-ethoxyethylphosphonate 
(17i): Colorless oil, yield 95%; IR (film): ν = 3325, 3209, 2988, 1614, 1563, 1467, 1408, 1221, 1052, 
1025 cm−1; 1H-NMR (300 MHz, CDCl3): δ = 7.99 (s, 1H, HC5′), 7.98 (s, 1H), 5.37 (s, 2H, CH2), 4.53 
(dd, J = 5.0 Hz, J = 4.8 Hz, 2H, PCH2CH2OCH2CH2), 4.14–4.03 (m, 4H, 2 × POCH2CH3), 3.80 (dd,  
J = 5.3 Hz, J = 5.0 Hz, 2H, PCCOCH2CH2), 3.70 (dt, J = 15.3 Hz, J = 7.0 Hz, 2H, PCH2CH2O), 2.05 
(dt, J = 18.5 Hz, J = 7.0 Hz, 2H, PCH2CH2O), 1.30 (t, J = 7.0 Hz, 6H, 2 × POCH2CH3); 13C-NMR 
(151 MHz, CDCl3): δ = 159.50, 153.55, 151.02, 142.28, 141.84, 124.73, 124.42, 68.82, 65.10 (d,  
J = 2.9 Hz, PCCO), 61.76 (d, J = 6.5 Hz, POC), 50.23, 38.53, 26.66 (d, J = 141.0 Hz, PC), 16.30 (d,  
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J = 6.2 Hz, POCC); 31P-NMR (121.5 MHz, CDCl3): δ = 28.55 ppm. Anal. calcd. for C16H24ClN8O4P: 
C, 41.88; H, 5.27; N, 24.42. Found: C, 42.01; H, 5.33; N, 24.60. 
Diethyl 2-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-acetamidoethylphosphonate 
(17j): White powder, yield 78%; m.p. = 193–195 °C; IR (KBr): ν = 3330, 3216, 2986, 1690, 1615, 1563, 
1468, 1409, 1215, 1023 cm−1; 1H-NMR (300 MHz, CDCl3): δ = 7.96 (s, 1H, HC5′), 7.86 (s, 1H), 7.20 
(br s, 1H, NHCO), 5.39 (s, 2H, CH2), 5.01 (s, 2H), 4.15–4.06 (m, 4H, 2 × POCH2CH3), 3.72 (dd,  
J = 11.9 Hz, J = 5.7 Hz, 2H, PCH2NH), 1.71 (br s, 2H, NH2), 1.29 (t, J = 6.9 Hz, 6H, 2 × POCH2CH3); 
13C-NMR (151 MHz, DMSO-d6): δ = 165.91, 160.39, 154.37, 149.91, 143.43, 142.48, 125.41, 123.69, 
62.32 (d, d, J = 6.1 Hz, POC), 51.92, 38.65, 34.70 (d, J = 155.2 Hz, PC), 16.66 (d, J = 5.5 Hz, POCC); 
31P-NMR (121.5 MHz, CDCl3): δ = 21.92 ppm. Anal. calcd. for C15H21ClN9O4P: C, 39.35; H, 4.62; N, 
27.54. Found: C, 39.57; H, 4.51; N, 27.47. 
(1R,2S)-Dibenzyl 3-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-2-benzyloxy-
1-hydroxypropylphosphonate ((1R,2S)-17k): Colorless oil, yield 84%; [α]20 D  = +9.6 (c = 1.12 in CHCl3); 
IR (film): ν = 3333, 3212, 1690, 1616, 1564, 1457, 1409, 1215, 1135 cm−1; 1H-NMR (300 MHz, CDCl3): 
δ = 7.96 (s, 1H, HC5′), 7.61 (s, 1H), 7.31–7.23 (m, 11H), 7.22–7.15 (m, 2H), 7.08–7.02 (m, 2H), 5.27 
(AB, JAB = 15.5 Hz, 1H, HCH), 5.22 (AB, JAB = 15.5 Hz, 1H, HCH), 5.08–4.96 (m, 4H, 2 × POCH2Ph), 
4.59 (dd, J = 14.1 Hz, J = 5.7 Hz, 1H, HCHN), 4.57 (d, J = 10.8 Hz, 1H, HCH-Ph), 4.47 (dd, J = 14.1 Hz,  
J = 7.0 Hz, 1H, HCHN), 4.32–4.20 (m, 1H, PCCH), 4.17 (d, J = 10.8 Hz, 1H, HCH-Ph), 3.91 (dd,  
J = 11.6 Hz, J = 3.2 Hz, 1H, PCH), 1.90–1.10 (very br s, 3H, NH2 and OH); 13C-NMR (151 MHz, 
CDCl3): δ = 159.18, 153.37, 151.45, 142.19, 141.81, 136.69, 135.77 (d, 5.8 Hz), 135.63 (d, 5.8 Hz), 
128.77, 128.71, 128.69, 128.43, 128.22, 128.20, 128.17, 125.02, 124.53, 74.06, 68.71 (d, J = 7.4 Hz, 
POC), 68.41 (d, J = 7.4 Hz, POC), 68.28 (d, J = 162.0 Hz, PC), 50.66 (d, J = 11.4 Hz, PCCC), 38.52;  
31P-NMR (121.5 MHz, CDCl3): δ = 22.35 ppm. Anal. calcd. for C32H32ClN8O5P: C, 56.93; H, 4.78; N, 
16.60. Found: C, 56.80; H, 4.52; N, 16.44. 
(1S,2S)-Dibenzyl 3-{4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-2-benzyloxy-
1-hydroxypropylphosphonate ((1S,2S)-17k): White solid, yield 84%; [α]20 D  = +22.9 (c = 0.096 in CHCl3); 
m.p. = 76–78 °C; IR (KBr): ν = 3384, 3213, 1617, 1563, 1457, 1409, 1214 cm−1; 1H-NMR (300 MHz, 
CDCl3): δ = 7.94 (s, 1H, HC5′), 7.64 (s, 1H), 7.38–7.20 (m, 11H), 7.20–7.10 (m, 2H), 7.00–6.95 (m, 2H), 
5.26 (s, 2H, CH2), 5.04 (d, J = 8.5 Hz, 2H, POCH2Ph), 5.01 (d, J = 9.5 Hz, 2H, POCH2Ph),4.73 (dd,  
J = 14.5 Hz, J = 3.2 Hz, 1H, HCHN), 4.60 (dd, J = 14.6 Hz, J = 6.5 Hz, 1H, HCHN), 4.39 (d, J = 11.1 Hz, 
1H, HCH-Ph), 4.24 (d, J = 11.1 Hz, 1H, HCH-Ph), 4.17–4.10 (m, 1H, PCCH), 4.03 (dd, J = 9.0 Hz,  
J = 5.5 Hz, 1H, PCH), 1.80–1.00 (very br s, 3H, NH2 and OH); 13C-NMR (151 MHz, CDCl3): δ = 159.16, 
153.40, 151.42, 142.23, 141.60, 136.66, 135.80 (d, J = 5.8 Hz), 135.70 (d, J = 5.8 Hz), 128.71, 128.68, 
128.43, 128.17, 128.14, 128.01, 125.02, 124.68, 77.64 (d, J = 5.2 Hz), 72.73, 68.64 (d, J = 7.4 Hz, 
POC), 68.45 (d, J = 7.4 Hz, POC), 67.77 (d, J = 161.6 Hz, PC), 50.28 (d, J = 5.8 Hz, PCCC), 38.56; 
31P-NMR (121.5 MHz, CDCl3): δ = 22.14 ppm. Anal. calcd. for C32H32ClN8O5P: C, 56.93; H, 4.78; N, 
16.60. Found: C, 56.71; H, 4.71; N, 16.31. 
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3.3. General Procedure for Transformation 17 into 16 
The respective 2-amino-6-chloropurine derivative 17a‒17j (1.00 mmol) was dissolved in a 75% 
aqueous solution of trifluoroacetic acid (6 mL) and left at room temperature overnight. The solvent 
was removed, and the residue was co-evaporated with water and subsequently with ethanol to give 
pure guanine derivatives 16a‒16j. 
Diethyl {4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}methylphosphonate 
(16a): A white powder, yield 98%; m.p. = 135–138 °C; IR (KBr): ν = 3330, 3131, 2988, 2935, 1720, 
1639, 1606, 1021 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 8.03 (s, 1H), 7.80 (s, 1H, HC5′), 5.37 (s, 2H, 
CH2), 5.02 (d, J = 13.1 Hz, 2H, PCH2), 4.16–4.07 (m, 4H, 2 × POCH2CH3), 1.25 (t, J = 7.1 Hz, 6H,  
2 × POCH2CH3); 13C-NMR (151 MHz, CD3OD): δ = 155.52, 154.83, 150.53, 141.37, 137.21, 125.53, 
109.68, 63.64 (d, J = 6.6 Hz, POC), 45.08 (d, J = 155.0 Hz, PC), 37.72, 15.28 (d, J = 5.5 Hz, POCC); 
31P-NMR (121.5 MHz, CD3OD): δ = 18.13 ppm. Anal. calcd. for C13H19N8O4P: C, 40.84; H, 5.01; N, 
29.31. Found: C, 40.98; H, 4.90; N, 29.44. 
Diethyl 2-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}ethylphosphonate 
(16b): A thick resin, yield 92%; IR (film): ν = 3441, 3129, 2986, 1692, 1537, 1480, 1377, 1204, 1051, 
1224 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 8.72 (s, 1H), 8.17 (s, 1H, HC5′), 5.48 (s, 2H, CH2), 4.66 
(dt, J = 13.4 Hz, J = 7.4 Hz, 2H, PCH2CH2), 4.09–3.99 (m, 4H, 2 × POCH2CH3), 2.52 (dt, J = 18.3 Hz, 
J = 7.4 Hz, 2H, PCH2), 1.25 (t, J = 7.0 Hz, 6H, 2 × POCH2CH3); 13C-NMR (151 MHz, CD3OD):  
δ = 160.27, 155.40, 150.63, 141.18, 137.39, 124.70, 110.47, 62.34 (d, J = 6.6 Hz, POC), 44.29 (d,  
J = 2.9 Hz, PCC), 38.99, 25.70 (d, J = 142.0 Hz, PC), 15.20 (d, J = 5.8 Hz, POCC); 31P-NMR (121.5 MHz, 
CD3OD): δ = 28.14 ppm. Anal. calcd. for C14H21N8O4P: C, 42.43; H, 5.34; N, 28.27. Found: C, 42.60; 
H, 5.55; N, 28.40. 
Diethyl 3-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}propylphosphonate 
(16c): Thick resin, yield 92%; IR (film): ν = 3437, 3134, 2940, 1693, 1538, 1479, 1376, 1228, 1053, 
1025 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 8.03 (s, 1H, HC5′), 7.89 (s, 1H), 5.36 (s, 2H, CH2), 4.47 
(t, J = 6.9 Hz, 2H, PCH2CH2CH2), 4.15–4.00 (m, 4H, 2 × POCH2CH3), 2.22–2.08 (m, 2H, PCH2CH2), 
1.83–1.71 (m, 2H, PCH2), 1.28 (t, J = 7.0 Hz, 6H, POCH2CH3); 13C-NMR (75.5 MHz, CD3OD):  
δ = 155.42, 155.07, 150.65, 141.14, 137.25, 124.56, 110.09, 62.09 (d, J = 6.7 Hz, POC), 53.50, 49.96 
(d, J = 18.2 Hz, PCCC), 39.15, 23.20 (d, J = 4.4 Hz, PCC), 21.57 (d, J = 143.5 Hz, PC), 15.34 (d,  
J = 5.7 Hz, POCC); 31P-NMR (121.5 MHz, CD3OD): δ = 32.57 ppm. Anal. calcd. for C15H23N8O4P: C, 
43.90; H, 5.65; N, 27.31. Found: C, 44.12; H, 5.77; N, 27.48. 
Diethyl 4-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}butylphosphonate 
(16d): An yellowish powder, yield 94%; m.p. = 106–108 °C; IR (KBr): ν = 3330, 3200, 3115, 2936, 
2739, 1731, 1694, 1634, 1483, 1388, 1221, 1025 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 8.03 (s, 1H, 
HC5′), 7.95 (s, 1H), 5.37 (s, 2H, CH2), 4.42 (t, J = 6.9 Hz, 2H, PCCCCH2), 4.13–3.96 (m, 4H,  
2 × POCH2CH3), 2.04 (qu, J = 6.9 Hz, 2H, PCCCH2), 1.80–1.73 (m, 2H, PCH2), 1.64–1.42 (m, 2H, 
PCCH2), 1.24 (t, J = 7.1 Hz, 6H, 2 × POCH2CH3); 13C-NMR (151 MHz, CD3OD): δ = 155.77, 154.21, 
150.35, 140.65, 137.06, 124.61, 108.53, 61.92 (d, J = 6.6 Hz, 2 × POC), 49.53, 39.48, 30.20 (d,  
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J = 15.8 Hz, PCCC), 23.68 (d, J = 140.9 Hz, PC), 19.07 (d, J = 5.2 Hz, PCC), 15.37 (d, J = 5.7 Hz, 
POCC); 31P-NMR (121.5 MHz, CD3OD): δ = 32.62 ppm. Anal. calcd. for C16H25N8O4P: C, 45.28; H, 
5.94; N, 26.40. Found: C, 45.40; H, 6.07; N, 26.55. 
Diethyl 2-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-
hydroxyethylphosphonate (16e): White powder, yield 98%; m.p. > 265 °C; IR (KBr): ν = 3428, 3134, 
3063, 2988, 1695, 1613, 1539, 1220, 1047, 1019 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 9.03 (s, 1H), 
8.24 (s, 1H), 5.03 (s, 2H, CH2), 4.77 (ddd, J = 14.5 Hz, J = 7.1 Hz, J = 3.5 Hz, 1H, PCCHaHb), 4.60 
(ddd, J = 14.5 Hz, J = 9.5 Hz, J = 6.6 Hz, 1H, PCCHaHb), 4.37 (dt, J = 9.5 Hz, J = 3.5 Hz, 1H, PCH), 
4.25–4.14 (m, 4H, 2 × POCH2CH3), 1.33 (t, J = 7.1 Hz, 6H, 2 × POCH2CH3); 13C-NMR (151 MHz, 
CD3OD): δ = 155.67, 154.47, 150.54, 140.52, 137.10, 125.84, 108.92, 66.72 (d, J = 167.5 Hz, PC), 63.49 
(d, J = 6.9 Hz, POC), 63.28 (d, J = 6.9 Hz, POC), 51.65 (d, J = 9.9 Hz, PCC), 39.27, 15.38 (d, J = 4.9 Hz,  
2 × POCC); 31P-NMR (121.5 MHz, CD3OD): δ = 21.83 ppm. Anal. calcd. for C14H21N8O5P × H2O: C, 
39.07; H, 5.39; N, 26.04. Found: C, 39.19; H, 5.30; N, 26.18. 
Diethyl 3-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-2-
hydroxypropylphosphonate (16f): White powder, yield 98%; m.p. = 144–147 °C; IR (KBr): ν = 3346, 
3218, 3218, 2985, 1618, 1564, 1468, 1409, 1220, 1025 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 8.71 
(s, 1H), 8.13 (s, 1H), 5.49 (s, 2H), 4.60 (dd, J = 13.7 Hz, J = 3.2 Hz, 1H, PCCCHaHb), 4.42 (dd,  
J = 13.7 Hz, J = 7.6 Hz, 1H, PCCCHaHb), 4.38–4.27 (m, 1H, PCCH), 4.18–4.06 (m, 4H, 2 × POCH2CH3), 
2.15 (ddd, J = 18.8 Hz, J = 15.5 Hz, J = 5.5 Hz, 1H, PCHaHb), 2.02 (ddd, J = 18.8 Hz, J = 15.5 Hz,  
J = 7.2 Hz, 1H, PCHaHb), 1.33 (t, J = 7.1 Hz, 3H, POCH2CH3), 1.32 (t, J = 7.1 Hz, 3H, POCH2CH3);  
13C-NMR (151 MHz, CD3OD): δ = 155.35, 155.30, 151.24, 140.86, 137.26, 125.52, 112.00, 65.30 (d, 
J = 2.5 Hz, PCC), 62.06 (d, J = 6.4 Hz, POC), 62.24 (d, J = 6.4 Hz, POC), 55.95 (d, J = 14.3 Hz, 
PCCC), 39.00, 30.51 (d, J = 140.6 Hz, PC), 15.28 (d, J = 6.1 Hz, 2 × POCC); 31P-NMR (121.5 MHz, 
CD3OD): δ = 29.71 ppm. Anal. calcd. for C15H23N8O5P × 2H2O: C, 38.96; H, 5.89; N, 24.23. Found: 
C, 39.16; H, 5.84; N, 24.33. 
Diethyl 3-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-
hydroxypropylphosphonate (16g): White powder, yield 98%; m.p. = 150–153 °C; IR (KBr): ν = 3330, 
3208, 3133, 2989, 2932, 1728, 1690, 1643, 1572, 1410, 1204, 1023 cm−1; 1H-NMR (300 MHz, CD3OD): 
δ = 8.44 (s, 1H), 8.10 (s, 1H), 5.44 (s, 2H, CH2), 4.60 (dd, J = 7.9 Hz, J = 5.9 Hz, 2H, PCCCH2), 4.21–4.08 
(m, 4H, 2 × POCH2CH3), 3.80 (ddd, J = 10.5 Hz, J = 7.1 Hz, J = 3.2 Hz, 1H, PCH), 2.43–2.03 (m, 2H, 
PCCH2), 1.31 (t, J = 7.1 Hz, 3H, POCH2CH3), 1.30 (t, J = 7.1 Hz, 3H, POCH2CH3); 13C-NMR (151 MHz, 
CD3OD): δ = 155.95, 154.99, 151.28, 141.57, 137.50, 124.47, 113.12, 63.67 (d, J = 168.1 Hz, PC), 
63.09 (d, J = 7.1 Hz, POC), 62.73 (d, J = 7.1 Hz, POC), 46.42 (d, J = 15.6 Hz, PCCC), 38.76, 31.79 (d,  
J = 4.1 Hz, PCC) 15.43 (d, J = 5.4 Hz, POCC), 15.39 (d, J = 5.4 Hz, POCC); 31P-NMR (121.5 MHz, 
CD3OD): δ = 25.35 ppm. Anal. calcd. for C15H23N8O5P × 2H2O: C, 38.96; H, 5.89; N, 24.23. Found: 
C, 38.72; H, 5.91; N, 24.39. 
Diethyl 2-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl} 
ethoxymethyphosphonate (16h): White powder, yield 98%; m.p. = 89–92 °C; IR (KBr): ν = 3330, 3136, 
2992, 2934, 1727, 1649, 1601, 1206, 1023 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 8.91 (s, 1H), 8.20 
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(s, 1H), 5.52 (s, 2H, CH2), 4.63 (t, J = 4.7 Hz, 2H, PCH2OCH2CH2), 4.11–4.01 (m, 4H, 2 × POCH2CH3), 
3.99 (t, J = 4.7 Hz, 2H, PCOCH2CH2), 3.87 (d, J = 8.5 Hz, 2H, PCH2O), 1.25 (t, J = 7.1 Hz, 6H,  
2 × POCH2CH3); 13C-NMR (151 MHz, CD3OD): δ = 155.52, 154.96, 150.52, 140.89, 137.19, 125.06, 
109.71, 70.94 (d, J = 6.6 Hz, POC), 70.86 (d, J = 6.6 Hz, POC), 64.06 (d, J = 166.6 Hz, PC), 62.81 (d,  
J = 6.6 Hz, PCOC), 49.94, 39.15, 15.35 (d, J = 5.5 Hz, POCC); 31P-NMR (121.5 MHz, CD3OD):  
δ = 22.51 ppm. Anal. calcd. for C15H23N8O5P×H2O: C, 40.54; H, 5.67; N, 25.22. Found: C, 40.44; H, 
5.50; N, 25.53. 
Diethyl 2-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl} 
ethoxyethyphosphonate (16i): Colorless oil, yield 98%; IR (film): ν = 3318, 3133, 2987, 2932, 1706, 
1639, 1604, 1202, 1051, 1027 cm−1; 1H-NMR (300 MHz, CD3OD): δ = 8.96 (s, 1H), 8.22 (s, 1H),  
5.02 (s, 2H, CH2), 4.59 (t, J = 5.3 Hz, 2H, PCH2CH2OCH2CH2), 4.08–3.98 (m, 4H, 2 × POCH2CH3), 3.86 
(t, J = 5.3 Hz, 2H, PCCOCH2CH2), 3.68 (dt, J = 16.4 Hz, J = 6.8 Hz, 2H, PCH2CH2O), 2.10 (dt,  
J = 18.2 Hz, J = 6.8 Hz, 2H, PCH2CH2O), 1.27 (t, J = 7.1 Hz, 6H, 2 × POCH2CH3); 13C-NMR (151 MHz, 
CD3OD): δ = 155.39, 154.20, 150.32, 141.04, 137.41, 125.01, 113.80, 68.51, 64.47 (d, J = 3.0 Hz, 
PCCO), 61.96 (d, J = 6.5 Hz, POC), 50.10, 39.09, 25.70 (d, J = 140.3 Hz, PC), 15.29 (d, J = 6.4 Hz, 
POCC); 31P-NMR (121.5 MHz, CD3OD): δ = 30.92 ppm. Anal. calcd. for C16H25N8O5P: C, 43.64; H, 
5.72; N, 25.44. Found: C, 43.74; H, 5.86; N, 25.66. 
Diethyl 2-{4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl} 
acetamidomethyphosphonate (16j): White powder, yield 98%; m.p. > 230 °C; IR (KBr): ν = 3331, 
3127, 2990, 2930, 1729, 1680, 1635, 1563, 1478, 1389, 1209, 1024 cm−1; 1H-NMR (300 MHz, CD3OD): 
δ = 8.84 (s, 1H), 8.17 (s, 1H), 5.52 (s, 2H, CH2), 5.23 (s, 2H), 4.18–4.08 (m, 4H, 2 × POCH2CH3), 3.74 
(brd, J = 11.9 Hz, 2H, PCH2NH), 1.30 (t, J = 6.9 Hz, 6H, 2 × POCH2CH3); 13C-NMR (151 MHz, 
CD3OD): δ = 166.37 (d, J = 3.4 Hz, C=O), 155.70, 154.66, 149.94, 140.70, 137.04, 126.11, 109.88, 
62.84 (d, J = 6.5 Hz, POC), 51.59, 39.25, 34.37 (d, J = 158.5 Hz, PC), 15.30 (d, J = 5.7 Hz, POCC); 
31P-NMR (121.5 MHz, CD3OD): δ = 22.20 ppm. Anal. calcd. for C15H22N9O5P: C, 41.00; H, 5.05; N, 
28.69. Found: C, 40.66; H, 4.89; N, 28.50. 
3.4. Antiviral Activity Assays 
The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) 
strain KOS, thymidine kinase-deficient (TK−) HSV-1 KOS strain resistant to acyclovir (ACVr), herpes 
simplex virus type 2 (HSV-2) strains Lyons and G, varicella-zoster virus (VZV) strain Oka, TK− VZV 
strain 07−1, human cytomegalovirus (HCMV) strains AD-169 and Davis, vaccinia virus Lederle  
strain, respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), Coxsackie B4,  
para-influenza 3, influenza virus A (subtypes H1N1, H3N2), influenza virus B, reovirus-1, Sindbis, 
reovirus-1, Punta Toro, human immunodeficiency virus type 1 strain IIIB and human immunodeficiency 
virus type 2 strain ROD. The antiviral, other than anti-HIV, assays were based on the inhibition of the 
virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, African 
green monkey cells (Vero), human epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK). 
Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 
being the virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU) (VZV) in 
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the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation 
was recorded as soon as it reached completion in the control virus-infected cell cultures that were not 
treated with the test compounds. Antiviral activity was expressed as the EC50 or compound concentration 
required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%. 
3.5. Cytostatic Activity Assays 
All assays were performed in 96-well microtiter plates. To each well were added (5−7.5) × 104 tumor 
cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine 
leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 
37 °C in a humidified CO2-controlled atmosphere. At the end of the incubation period, the cells were 
counted in a Coulter counter. The IC50 (50% inhibitory concentration) was defined as the concentration 
of the compound that inhibited cell proliferation by 50%. 
4. Conclusions  
A novel series of {4-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-1H-1,2,3-triazol-1-yl}alkylphosphonates 
17 was synthesized and subsequently transformed into {4-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl) 
methyl]-1H-1,2,3-triazol-1-yl}alkylphosphonates 16 as acyclic analogues of guanosine. Evaluation of 
the antiviral activity of phosphonates 17a–k, as well as 16a–j was performed against a broad variety of 
DNA and RNA viruses; however, none of them was found active at concentrations up to 250 μM. The 
cytostatic properties of Compounds 17a–k and 16a–j were studied on L1210, CEM and HeLa cell lines. 
Among them, Compounds (1R,2S)-17k and (1S,2S)-17k were moderately active toward L1210 and 
CEM cells (IC50 in the 16–30 µM range). 
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